Skip to main content
Pentixapharm Holding AG logo

Pentixapharm Holding AG - Investor Relations & Filings

Listed IPO Mar 2024
Ticker · PTP ISIN · DE000A40AEG0 LEI · 3912005VBOVXNDXEQZ36 F Manufacturing
Open in API
Filings indexed 66 across all filing types
Latest filing 2026-07-09 Director's Dealing
Country DE Germany
Listing F PTP · 7 venues

About Pentixapharm Holding AG

https://www.pentixapharm.com/

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Recent filings

Filing Released Lang Actions
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, Granting of 8.922.464 Subscription rights
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person closely associated with a member of the administrative or supervisory body (Dr. Andreas Eckert). It explicitly uses the header 'Directors’ Dealings' and follows the standard regulatory format for disclosing transactions by persons discharging managerial responsibilities (PDMRs). This aligns perfectly with the definition for 'Director's Dealing' (DIRS).
2026-07-09 English
Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [68Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism
Regulatory Filings Classification · 95% confidence The document is an 'Ad-hoc' announcement regarding a regulatory development (FDA Fast Track designation) for a company's product candidate. It is a corporate news release issued under Article 17 of the EU Market Abuse Regulation (MAR). It does not fit into specific categories like financial reports, board changes, or share transactions. As it is a general regulatory/corporate announcement that does not fit other specific categories, it falls under the RNS (Regulatory Filings) category.
2026-07-09 English
Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
Capital/Financing Update Classification · 100% confidence The document is an official announcement regarding a rights issue (capital increase) by Pentixapharm Holding AG. It details the offering volume, subscription ratio, subscription price, and the commitment of a major shareholder. This falls squarely under the definition of a capital/financing update, as it describes a specific corporate action to raise capital through the issuance of new shares.
2026-07-01 English
Pentixapharm Holding AG: FDA grants Study May Proceed for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Regulatory Filings Classification · 95% confidence The document is an 'Ad-hoc' disclosure under Article 17 of the Market Abuse Regulation (MAR). It covers multiple topics: FDA approval for a clinical trial, an intended capital increase (share issuance), and a regulatory enforcement review by BaFin regarding previous financial statements. While it mentions financial reporting, it is not a financial report itself, but rather a regulatory announcement of material events. Given the mix of capital measures and regulatory updates, 'RNS' (Regulatory Filings) is the most appropriate classification as it serves as the catch-all for regulatory disclosures that do not fit into more specific categories like 'SHA' (which is for the actual issuance) or 'CAP' (which is for the financing update).
2026-06-09 English
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
Regulatory Filings Classification · 87% confidence The document is a corporate press release announcing submission of an IND application to the FDA for a Phase 3 clinical trial. It does not contain financial results, director changes, voting results, or substantive financial statements, nor is it a presentation or investor material. It is a regulatory announcement/fallback filing. Therefore, it best fits into the “Regulatory Filings” category.
2026-05-11 English
Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of Pentixapharm's first quarter 2026 financial results, including financial highlights, business updates, regulatory progress, and leadership changes. It contains substantive financial data such as net loss, EBITDA, cash flow, and assets for the quarter ended March 31, 2026. The document also discusses operational progress and strategic outlook, typical of an interim financial report. It explicitly states that the full interim financial statements are available on the company's website, indicating this document itself is a comprehensive quarterly report rather than just an announcement of report availability. The length of the document (over 10,000 characters) and the inclusion of detailed financial and operational information confirm it is an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.